Search

for
Search:

Sort by

Research

840-870 / 1000+ results

Phenytoin or Spironolactone Intervention Counteracts 5-Fluorouracil-Induced Alopecia in Rats by Suppressing Oxidative Stress and Inflammation While Promoting Collagen Synthesis

research Phenytoin or Spironolactone Intervention Counteracts 5-Fluorouracil–Induced Alopecia in Rats by Suppressing Oxidative Stress and Inflammation While Promoting Collagen Synthesis

November 2025 in “Preprints.org”

Phenytoin and spironolactone help prevent hair loss from chemotherapy by reducing stress and inflammation.

research Finasteride < Rec INN; BAN; USAN >

5 citations , January 1991 in “Drugs of The Future”

research Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor

16 citations , December 2012 in “Bioinformation”

Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.

Synthesis of Spiro[cyclohexane-1,2'-[2H]indene] Derivatives as Inhibitors of Steroid 5α-Reductase

research Synthesis of Spiro[cyclohexane-1,2?-[2H]indene] derivatives as inhibitors of steroid 5?-reductase

8 citations , June 1995 in “Helvetica Chimica Acta”

Compound 15a was effective in inhibiting 5α-reductase.

research Alpha-blockers/finasteride: no benefit in ED

September 2003 in “Reactions Weekly”

research Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study

November 2023 in “SKIN The Journal of Cutaneous Medicine”

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

BAYONET Trial: Staged Combination With Encorafenib, Binimetinib, Plus Cetuximab Following Encorafenib Plus Cetuximab for BRAF V600E-Mutant Metastatic Colorectal Cancer

research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer

June 2024 in “ESMO Gastrointestinal Oncology”

The combination treatment showed a higher response rate but no significant survival benefits.

research Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition

1 citations , May 2026 in “Journal of Dermatological Treatment”

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

research Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata

4 citations , April 2024 in “Journal of Drugs in Dermatology”

Ruxolitinib cream may help treat severe hair loss in children.

research Rosacea-Like Dermatitis Caused by Icotinib Hydrochloride: A Case Report

June 2019 in “International journal of dermatology and venereology”

A man developed skin issues from cancer medication, which improved with specific treatments.

research Reply by the authors

September 2004 in “Urology”

Dutasteride may help prevent prostate cancer, but more research is needed.

research Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib

12 citations , January 2016 in “Journal of clinical biochemistry and nutrition”

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial

4 citations , March 2025 in “The Journal of Dermatology”

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

research Finasteride blocks progesterone synthesis in MA-10 Leydig tumor cells

3 citations , October 1993 in “Endocrinology”

PSS20 Mediation Modeling and Measurement Characteristics of the Itch Severity Score from a Phase 2B Trial of Oral CP-690-550 in Patients with Moderate-to-Severe Plaque Psoriasis

research PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS

May 2011 in “Value in Health”

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

research 026 Targeting pathogenic MICA-NKG2D interactions by statins: A novel adjunct treatment strategy for alopecia areata management?

November 2022 in “Journal of Investigative Dermatology”

Statins may help treat alopecia areata by reducing harmful immune interactions.

research Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis

December 2025 in “International Neurourology Journal”

Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.

research Downregulation of nuclear factor-kappaB activation in human keratinocytes by melanogenesis inhibitors

May 2004 in “International Journal of Cosmetic Science”

Melanogenesis inhibitors like kojic acid and niacinamide can reduce inflammation and pigment production in skin cells.

research Enzyme-linked immunosorbent assays for doping control of 5α-reductase inhibitors finasteride and dutasteride

10 citations , May 2010 in “Analytica Chimica Acta”

New tests detect finasteride and dutasteride in urine quickly and easily.

research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

408 citations , May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.

research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)

5 citations , April 2019 in “Journal of Investigative Dermatology”

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

research P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis

January 2019 in “프로그램북(구 초록집)”

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

October 2025 in “Dermatology and Therapy”

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

research Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials

October 2025 in “Postgraduate Medical Journal”

This study conducted a network meta-analysis to compare the efficacy of different Janus kinase (JAK) inhibitors in treating severe alopecia areata (AA), involving 3,866 patients across various trials. The analysis found that deuruxolitinib at 12 mg showed the best efficacy, although with wider confidence intervals, while baricitinib at 4 mg demonstrated significant efficacy with high precision (OR: 2.59, 95% CI: 1.98-3.38). The study confirms the effectiveness of JAK inhibitors in treating severe AA and highlights their dose-dependent effects, providing valuable guidance for clinicians in selecting appropriate treatments. Future research is encouraged to further compare JAK inhibitors to strengthen treatment regimens for AA.

research The effect of polyphloretin phosphate, polyoestradiol phosphate, a diphosphonate and a polyphosphate on calcification induced by dihydrotachysterol in skin, aorta and kidney of rats

31 citations , February 1972 in “Experientia”

The diphosphonate was the most effective at preventing calcification in rats.

research 72751 Janus Kinase Inhibitors for Alopecia Universalis: A Systematic Review

July 2026 in “Journal of the American Academy of Dermatology”

Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis Explaining Paradoxical Results

research Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results

5 citations , August 2018 in “Sexual Medicine Reviews”

5α-Reductase inhibitors do not consistently increase testosterone levels in the blood.

The Role of Janus Kinase Inhibitors in Dermatology

← Previous page Next page →